New York | Jan, 2026 — Vanda Pharmaceuticals Inc. achieved a major regulatory and commercial milestone after the U.S. Food and Drug Administration (FDA) approved Nereus (tradipitant) for the treatment of motion-sickness–related vomiting, becoming the first new therapy approved for this indication in decades.
Following the approval, Vanda’s shares rose approximately 18% in premarket trading, reflecting strong investor optimism as the company transitions from a prolonged regulatory phase into commercial execution.
Nereus is an oral neurokinin-1 (NK-1) receptor antagonist, designed to block central nervous system pathways associated with nausea and vomiting triggered by motion-related sensory mismatch. The FDA’s decision was supported by two late-stage clinical trials involving 681 patients, which demonstrated statistically significant reductions in vomiting episodes compared with placebo.
Commercial Launch and Revenue Outlook
Vanda stated that it plans to commercially launch Nereus in the coming months, placing near-term focus on pricing strategy, payer coverage, and early uptake. Analysts have highlighted the approval as a potential inflection point for the company, with estimates suggesting that U.S. peak annual sales could exceed $100 million based solely on the motion-sickness indication.
The approval positions Nereus in a competitive landscape that includes long-established therapies such as prescription scopolamine patches and over-the-counter antihistamine-based products, though Nereus introduces a differentiated oral, mechanism-based option.
Regulatory Turning Point
The FDA approval follows a significant regulatory shift in December, when the agency lifted a partial clinical hold after determining that motion sickness is an acute, self-limiting condition, removing the requirement for additional long-term toxicology studies. This decision streamlined the regulatory pathway and accelerated approval.
Safety Profile and Label Considerations
In placebo-controlled trials, commonly reported adverse reactions included somnolence and fatigue. Vanda noted that Nereus may impair the ability to drive or operate machinery, and appropriate labeling reflects these considerations.
Pipeline Expansion Opportunities
Tradipitant was originally licensed from Eli Lilly and is also being evaluated by Vanda in gastroparesis and for nausea and vomiting associated with GLP-1 receptor agonist therapies, including treatments used in diabetes and obesity. These additional indications represent potential long-term growth opportunities beyond the initial approval.
Strategic Significance
The FDA approval of Nereus marks a transformational milestone for Vanda Pharmaceuticals, shifting the company’s narrative from regulatory uncertainty to commercial execution. As the company enters 2026, investors and industry observers will closely monitor launch performance, reimbursement dynamics, and lifecycle expansion efforts.
By